-
Product Insights
NewNet Present Value Model: Ionis Pharmaceuticals Inc’s Eplontersen Sodium
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewNet Present Value Model: Denali Therapeutics Inc’s DNL-788
Empower your strategies with our Net Present Value Model: Denali Therapeutics Inc's DNL-788 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Net Present Value Model: Rocket Pharmaceuticals Inc’s RPL-301
Empower your strategies with our Net Present Value Model: Rocket Pharmaceuticals Inc's RPL-301 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Net Present Value Model: Rocket Pharmaceuticals Inc’s Mozafancogene Autotemcel
Empower your strategies with our Net Present Value Model: Rocket Pharmaceuticals Inc's Mozafancogene Autotemcel report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Net Present Value Model: Rocket Pharmaceuticals Inc’s Ladilen
Empower your strategies with our Net Present Value Model: Rocket Pharmaceuticals Inc's Ladilen report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RPL-301 in Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RPL-301 in Anemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RPL-301 in Anemia Drug Details:RPL-301 is under development for the treatment of pyruvate kinase...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YPEG-Somatropin in Idiopathic Short Stature
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.YPEG-Somatropin in Idiopathic Short Stature Drug Details:YPEG-somatropin is under development for the treatment of growth hormone...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RP-2 in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RP-2 in Sarcomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RP-2 in Sarcomas Drug Details:RP-2 is under development for the treatment of mixed advanced...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iopofosine I-131 in Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iopofosine I-131 in Brain Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Iopofosine I-131 in Brain TumorDrug Details:Iopofosine I-131 (CLR-131) is under development for...
-
Company Insights
Innovation and Patenting activity of Rocket Pharmaceuticals Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Rocket Pharmaceuticals Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...